Advaxis Inc., of Princeton, N.J., named Anthony (Tony) Lombardo interim CEO.

Appili Therapeutics Inc., of Halifax, Nova Scotia, appointed Sean McBride vice president, business development.

Ascentage Pharma Group, of Taizhou, Zhejiang, appointed Han Li chief financial officer. Bone Therapeutics SA, of Gosselies, Belgium, named Steve Swinson board chairman, and appointed Dirk Dembski a non-executive director.

Axsome Therapeutics Inc., of New York, appointed John Golubieski chief financial officer, effective Aug. 4.

Breath Therapeutics Holding BV, of Munich, Germany, appointed Melissa Yeager chief regulatory officer.

Caribou Biosciences Inc., of Berkeley, Calif., named Steven B. Kanner chief scientific officer.

Diffusion Pharmaceuticals LLC, of Charlottesville, Va., added Robert R. Ruffolo Jr. to its board.

Evolva Holding SA, of Reinach, Switzerland, named Simon Waddington CEO.

Ferring Pharmaceuticals SA, of Saint-Prex, Switzerland, named Lars Peter Brunse executive vice president and chief production officer.

Fortress Biotech Inc., of New York, appointed Robyn Hunter chief financial officer, and named Lucy Lu president and CEO of its subsidiary Avenue Therapeutics Inc.

Oxthera AB, of Stockholm, appointed Matthew Gantz CEO.

Purdue Pharma (Canada), of Pickering, Ontario, part of Purdue Pharma LP, named Tom Koutsavlis vice president, research and development.

Scholar Rock Inc., of Cambridge, Mass., appointed David L. Hallal chairman of the board.